Imugene: Serious inroads – a highly successful cancer drug trial

Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N’ Bears Report about Imugene’s successful clinical trial of its immunotherapy for stomach cancer that showed material increases in overall survival rates with one patient still showing promising signs over 900 days later. 

See omnystudio.com/listener for privacy information.